Send to

Choose Destination
Clinicoecon Outcomes Res. 2017 Oct 3;9:585-594. doi: 10.2147/CEOR.S141061. eCollection 2017.

Utilization of fetal fibronectin testing and pregnancy outcomes among women with symptoms of preterm labor.

Author information

Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Sciences Center, Houston, TX, USA.
Avalere Health, LLC, Health Economics and Outcomes Research, Washington, DC, USA.
Hologic, Inc., Outcomes Research, Marlborough, MA, USA.
Department of Obstetrics and Gynecology, Santa Clara Valley Medical Center, San Jose, CA, USA.



To identify pregnant health plan members triaged through the emergency department (ED), including labor and delivery (ELD) units, with symptoms of preterm labor (PTL), and evaluate the use of fetal fibronectin (fFN) testing; and to calculate the rate of hospitalization and timing of delivery in relation to the ED visit.


Retrospective cohort study using Medical Outcomes Research for Effectiveness and Economics Registry®, a national multipayer claims database. A cohort of pregnant women evaluated in an ELD with a diagnosis of PTL from June 2012 through November 2015 was identified. The proportion of women with PTL who received fFN testing was calculated.


A total of 23,062 patients met the criteria for inclusion in the study. The rate of fFN testing prior to delivery was 12.0%. Of the 23,062 patients included in the analysis, 75.9% were discharged home. Of those who were discharged from the emergency room, one in five went on to deliver within 3 days and almost 96% of this group was not screened for the presence of fFN. Of the remaining 24.1% of patients admitted to the hospital, 91.3% delivered during their stay. In a sensitivity analysis, the percentage of women who delivered within 3 days of the ELD encounter was lower for women who received fFN testing only (6.6%) versus those who had a history of transvaginal ultrasound (TVUS) only (21.6%). Furthermore, the rate of delivery within 3 days was lowest among patients who had both fFN testing and TVUS (4.7%).


The utilization of fFN testing is 12%. The majority of pregnant patients triaged through the ELD with symptomatic PTL do not receive an fFN test. As part of PTL evaluation, fFN testing may identify women at increased risk for preterm delivery and help determine appropriate patient management.


emergency department; fetal fibronectin testing; pregnancy; preterm labor

Conflict of interest statement

Disclosure EMS, AAP and XS are employees of Avalere Health, LLC which received funding from Hologic, Inc. to support the execution of this study and development of the paper. KAT is an employee of Hologic, Inc. SCB and JDB serve as medical experts but received no support for their participation in this paper. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center